Triple Reuptake Inhibitors: A Premise and Promise - Wikidata - wikimedia - TriplyDB

Triple Reuptake Inhibitors: A Premise and Promise

Triple Reuptake Inhibitors: A Premise and Promise

http://www.wikidata.org/entity/Q28972234

about

sameAs

Pain and depression: a neurobiological perspective of their relationship Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Discovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporter Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder Treatment-resistant depression: therapeutic trends, challenges, and future directions.Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets.Curcumin as a putative antidepressant.Criticisms of drugs in early development for the treatment of depression: what can be improved?Agomelatine: a new option for treatment of depression?

P2860

Q28081471-E069D528-1C75-4152-9B07-0AC3BB74D6E2 Q33799660-52247716-1E8E-4211-9A24-C39E95B7DA28 Q34249476-3272DE51-F1FF-4A57-9421-8DC0DA7F5BBE Q35536869-ABE2AA40-6330-4E6B-AF4E-D54962875597 Q35997448-E0940BAE-9590-4A3B-86CD-C8C94C974FE8 Q37891098-256D0F3F-EC55-4561-B866-205D6C31E998 Q38167857-BE387836-1150-47E4-8DC0-FAAB37AEC815 Q38341731-D03E1427-B8EC-401D-9520-FAF9FA548FBF Q48148268-3DDA0363-3AF4-4E66-8A8D-3CC335E2076B Q48375336-41407DD7-8D3C-4918-8C18-06879CD95AEE

P2860

Triple Reuptake Inhibitors: A Premise and Promise

http://www.wikidata.org/entity/Q28972234

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Triple Reuptake Inhibitors: A Premise and Promise

@ast

Triple Reuptake Inhibitors: A Premise and Promise

@en

type

label

Triple Reuptake Inhibitors: A Premise and Promise

@ast

Triple Reuptake Inhibitors: A Premise and Promise

@en

prefLabel

Triple Reuptake Inhibitors: A Premise and Promise

@ast

Triple Reuptake Inhibitors: A Premise and Promise

@en

P1433

Q28972234-ABA76191-BB78-4310-8128-E76777E0FCE7

P1476

Q28972234-B3CA45B0-2B8A-41AA-8358-981A6E3F349D

P2093

Q28972234-6603CFEE-7DAB-4783-A074-1284FD854EA6

Q28972234-CF8EAF66-CCEB-4C6E-9FA2-88730916EC95

Q28972234-E5C19CF6-9B66-4317-9006-FFC240C3C39F

P2860

Q28972234-026B87EE-8B59-4E39-90F6-716034277362

Q28972234-0283F010-BA43-44FB-BEFA-4C4666007496

Q28972234-045AE568-09DA-4FC4-AE9C-751732ACE5DA

Q28972234-0510BD94-4250-42AC-824F-AA68A0F00F57

Q28972234-0AB7F485-2D72-475F-85F2-81AA656FABA4

Q28972234-14B8B5A8-0ABE-41AB-BC4F-A7336C3C0030

Q28972234-21024941-E951-458B-80C7-56E3CAA48939

Q28972234-2399DCFC-65B8-409F-BA29-DC23668C1A74

Q28972234-2B6CEA3A-6023-47C6-8436-9B08BB733897

Q28972234-2BC43E6E-0900-4E3F-AAAC-C33DF70F82E3

P304

Q28972234-11CFF709-9383-40C2-AC5F-790E87A44912

P31

Q28972234-4B2B1246-10AB-4D5B-9C51-7947304250B1

P356

Q28972234-16AEF763-98AD-466C-A074-5D72B24CCF9D

P433

Q28972234-7A6FBC97-A94B-4124-9700-D258C4B6B688

P478

Q28972234-23FC74DC-7023-4D5A-9AF6-C4F497649582

P577

Q28972234-3CA113DB-F2DA-42AB-810F-E6D8951C39BE

P5875

Q28972234-E541ADC2-0AAB-4408-8165-E8DC448A71A7

P698

Q28972234-C848EDD6-3E65-4D4F-8A8D-DAC50EF0CA85

P932

Q28972234-4728C0F4-35C2-4765-BAD0-09F19735A25E

P356

PI.2008.5.3.142

P1433

Psychiatry investigation

P1476

Triple Reuptake Inhibitors: A Premise and Promise

@en

P2093

Marks DM

http://www.w3.org/2001/XMLSchema#string

Pae CU

http://www.w3.org/2001/XMLSchema#string

Patkar AA

http://www.w3.org/2001/XMLSchema#string

P2860

Antidepressant therapy for unexplained symptoms and symptom syndromes

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat

Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine

Drug discovery: playing dirty

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain

DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

P304

142-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4306/PI.2008.5.3.142

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40834415

http://www.w3.org/2001/XMLSchema#string

P698

20046357

http://www.w3.org/2001/XMLSchema#string

P932

2796030

http://www.w3.org/2001/XMLSchema#string